Literature DB >> 9600708

Role of endogenous pro-enkephalin A-derived peptides in human T cell proliferation and monocyte IL-6 production.

S Kamphuis1, F Eriksson, A Kavelaars, J Zijlstra, M van de Pol, W Kuis, C J Heijnen.   

Abstract

In this paper, we describe that met-enkephalin and/or enkephalin-containing intermediary peptides of the prohormone pro-enkephalin A are produced and secreted by human peripheral blood T cells and monocytes. The peptides are produced after stimulation with the mitogenic monoclonal antibodies anti-CD2.1/2.2 and anti-CD28. In monocytes, enkephalin synthesis was induced by stimulation with lipopolysaccharide. We demonstrate here that these immune cell-derived enkephalins play an important regulatory role in the immune response. By using an anti-sense oligonucleotide strategy we could block the production of enkephalins. Blockade of the production of met-enkephalin and enkephalin-containing intermediary peptides resulted in enhancement of the proliferative T cell response and inhibition of monocyte IL-6 secretion. In vitro reconstitution of the anti-sense treated cultures with synthetic met-enkephalin or the delta-type specific opioid receptor agonist deltorphin could reverse inhibition of monocyte IL-6 production, suggesting that endogenous enkephalins act via membrane opioid receptors. In contrast, addition of met-enkephalin or deltorphin to the anti-sense treated T cell cultures did not have any effect on T cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9600708     DOI: 10.1016/s0165-5728(97)00240-3

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  8 in total

1.  Regulated proenkephalin expression in human skin and cultured skin cells.

Authors:  Andrzej T Slominski; Michal A Zmijewski; Blazej Zbytek; Anna A Brozyna; Jackie Granese; Alexander Pisarchik; Andre Szczesniewski; Desmond J Tobin
Journal:  J Invest Dermatol       Date:  2010-12-30       Impact factor: 8.551

2.  Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial.

Authors:  Jill P Smith; Sandra I Bingaman; Francesca Ruggiero; David T Mauger; Aparna Mukherjee; Christopher O McGovern; Ian S Zagon
Journal:  Dig Dis Sci       Date:  2011-03-08       Impact factor: 3.199

Review 3.  Potential Neuroimmune Interaction in Chronic Pain: A Review on Immune Cells in Peripheral and Central Sensitization.

Authors:  Jia-Xuan Yang; Hong-Fei Wang; Ji-Zhun Chen; Han-Yu Li; Ji-Chen Hu; An-An Yu; Jun-Jun Wen; Si-Jia Chen; Wei-Dong Lai; Song Wang; Yan Jin; Jie Yu
Journal:  Front Pain Res (Lausanne)       Date:  2022-07-04

Review 4.  T Cells as Guardians of Pain Resolution.

Authors:  Annemieke Kavelaars; Cobi J Heijnen
Journal:  Trends Mol Med       Date:  2021-01-08       Impact factor: 11.951

5.  Exploring the pharmacological potential of promiscuous host-defense peptides: from natural screenings to biotechnological applications.

Authors:  Osmar N Silva; Kelly C L Mulder; Aulus E A D Barbosa; Anselmo J Otero-Gonzalez; Carlos Lopez-Abarrategui; Taia M B Rezende; Simoni C Dias; Octávio L Franco
Journal:  Front Microbiol       Date:  2011-11-22       Impact factor: 5.640

6.  Endogenous opioid analgesia in peripheral tissues and the clinical implications for pain control.

Authors:  Daniel Kapitzke; Irina Vetter; Peter J Cabot
Journal:  Ther Clin Risk Manag       Date:  2005-12       Impact factor: 2.423

Review 7.  Opiate Drugs with Abuse Liability Hijack the Endogenous Opioid System to Disrupt Neuronal and Glial Maturation in the Central Nervous System.

Authors:  Kurt F Hauser; Pamela E Knapp
Journal:  Front Pediatr       Date:  2018-01-23       Impact factor: 3.418

Review 8.  Potentials of Neuropeptides as Therapeutic Agents for Neurological Diseases.

Authors:  Xin Yi Yeo; Grace Cunliffe; Roger C Ho; Su Seong Lee; Sangyong Jung
Journal:  Biomedicines       Date:  2022-02-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.